List of Antibody Drug Conjugates Companies with Phase 1 Active Clinical Trial - 27

ABL Bio Inc. (Kosdaq: 298380) is a South Korean biotechnology company dedicated to the development of bispecific antibody therapeutics to improve and save people's lives. With our BsAb platforms ‘Grabody-T,’ ‘Grabody-I’ and ‘Grabody-B,’ we have built a robust pipeline of multiple clinical and pre-clinical stage drug candidates. In the oncology area, we have developed Grabody-T, a modular 4-1BB engaging platform that has demonstrated excellent efficacy and safety. We also created a next-generation antibody drug conjugate program to treat various cancers. In the neurodegenerative disorder space, we have developed Grabody-B platform, which is designed to maximize blood-brain barrier (BBB) penetration. Grabody-B is applicable to various CNS targets across a plethora of neurological disorders, potentially providing a breakthrough to address the high unmet medical needs in neurodegeneration. We continue to actively expand and advance our pipeline through global strategic partnerships. For more information, please visit http://ablbio.com

Adcentrx Therapeutics is a biotechnology company focused on accelerating breakthroughs in protein conjugate therapeutic development for cancer and other life-threatening diseases. By combining the targeting precision of biologics and the disease fighting power of small molecule payloads, Adcentrx strives to develop next generation targeted therapies for improving patient treatment options.

Ajinomoto is a global leader in the research, development, manufacture and sale of amino acid-based products for the pharmaceutical, nutraceutical, sports nutrition, health and beauty industries as well as food ingredients and consumer food products.

Angiex Inc. is a privately held biotech startup whose mission is to exploit newly discovered biological transport mechanisms to make drugs with revolutionary power over cancer. Based in Cambridge, Mass., Angiex was founded by a scientific team of leading experts in angiogenesis, vascular biology, and oncology. The company is developing a novel portfolio of Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs) that release therapeutic payloads directly into the nucleus or cytosol, where the site of payload action is located.

Anwita Biosciences, Inc. is a clinical stage biopharmaceutical company headquartered in the San Francisco Bay Area. We are advancing our product pipeline of improved cytokines (Exenokines, Mableukins etc) and tumor-targeting antibody drug conjugates. Our lead product, Exenokine-21, has been accepted by China NMPA and the US FDA to initiate clinical studies. Our mission is to deliver transformative treatment options to improve the lives of patients with cancer and autoimmune diseases. We specialize in the discovery and development of optimized immunotherapeutics, leveraging our core expertise in cancer immunotherapy, bioinformatics, and target-based protein evolution.

Arbele is a locally grown pharmaceutical biotech focused on immunotherapy of cancers, immune disorders and neurological diseases. The company founding team has a strong combination of business development and pharmaceutical R&D, with an accumulation of >30 year experience in multinational drug companies. Our motto is to excel patient healthcare through innovation and breakthrough. Our mission is to deliver innovative and cost-effective therapeutics to treat diseases of unmet needs. We focus on antibody-based therapeutic platforms, including chimeric antigen receptor (CAR)-T and Bi-specific antibody technology, while leveraging new technology on CRISPR genome editing. Our culture ingredients are “integrity and social values”.

Our mission is to shape the future of medicine by developing safe and efficacious drugs, and high performing diagnostics, based on our proprietary Affimer® and pre|CISIONᵀᴹ platforms. The Affimer® platform is a novel class of biotherapeutic based on a naturally occurring human protein. It is Avacta’s proprietary therapeutic platform with its intellectual property covered by several patent families. Avacta’s proprietary pre|CISIONᵀᴹ targeted chemotherapy platform, releases active drug only in the tumour, thereby limiting systemic exposure and improving the overall safety and therapeutic potential of these powerful anti-cancer treatments. Avacta expects to take its first pre|CISIONᵀᴹ drug candidate, AVA6000, a targeted form of the standard-of-care Doxorubicin, into the clinic by the second half of 2021. By combining these two platforms the Company is building a pipeline of novel cancer therapies with the aim of creating effective treatments for all cancer patients including those who do not respond to existing immunotherapies. Avacta’s diagnostics division, based in Wetherby, UK., utilises it’s proprietary Affimer® platform to develop high performing diagnostics and works with partners world-wide to develop Affimer reagents with the objective of establishing royalty bearing license deals.

Axcynsis Therapeutics is at the forefront of developing cutting-edge Antibody Drug Conjugate (ADC) therapies. Our team's profound expertise, pioneering and proprietary ADC technology platform, enduring IP and know-how, substantial market opportunities, and strategic and effective execution position us as industry leaders in innovative cancer treatment solutions. At Axcynsis, our groundbreaking Matrix Optimization Platform is the cornerstone of our research and development efforts. This cutting-edge platform empowers us to swiftly explore numerous linker and payload combinations alongside our proprietary antibodies. We further harness state-of-the-art technologies, including an exclusive payload library derived from an FDA-approved drug and site-specific conjugation methods. These innovations are strategically employed to enhance the safety and quality of our ADCs. With two potential best-in-class programs on track for clinical trials by 2025 and a third program making headway toward IND status, we are poised for significant value creation and breakthroughs in cancer therapeutics. Based in Singapore, we plan to expand our clinical development operations to the United States by 2024. Join us on our journey to transform cancer treatment and make a meaningful impact in biotechnology. Axcynsis is at the forefront of developing life-changing ADC therapies, and we invite you to be a part of our innovative and dedicated team as we pioneer the future of cancer therapeutics.

Bright Peak are developing a portfolio of first-in-class and best-in-class cytokines with optimized biological properties for the treatment of cancer and autoimmune diseases. Through a variety of proprietary technology platforms, Bright Peak is uniquely abled to conjugate its cytokines as payloads to antibodies, creating bespoke, novel and proprietary “Bright Peak Immunocytokines”, and to other cytokines as “duokines”. The Bright Peak Immunocytokines allow tissue- and cell-specific targeting of the cytokine payload with the added potential for significantly enhanced efficacy. One of the many advantages of our approach is its "off-the-shelf" feature. Using a pioneering site-specific ADC-like chemical conjugation technology, any therapeutic antibody at any stage of development can be conjugated with Bright Peak’s cytokine payloads of choice, eliminating the current complexities of antibody engineering and cell line development. Bright Peak’s team works with a passion for innovation and bold science. We are an international research-driven organization dedicated to discovering and developing cutting edge therapies that will make a difference in the lives of patients. We aim to create a vibrant and international corporate culture and are currently hiring in our Basel, Switzerland and Southern California locations.

With a passion for outsmarting relentless cancers and autoimmune diseases, Byondis takes precision medicines to the next level. We are driven by one goal: providing novel treatments with high efficacy and low systemic toxicity for patients with high unmet medical needs. Many companies work in the areas of unmet need. What differentiates Byondis is its focus on producing a broad spectrum of molecular concepts, ranging from small molecule chemistries to complex protein structures. We engineer smaller and larger molecular functionalities that may be combined to target the right part of the body. This involves: • Next generation antibody-drug conjugates (ADCs), including proprietary linker-drug (LD) technology to generate multiple ADC candidates targeting different indications • Site-specific conjugation technology • Monoclonal antibodies (mAbs) • Highly selective, disease-targeting small molecules The success of our company fully depends on our people. To them, we aim to provide a fair, open and inspiring working environment, where there is room for ambition, entrepreneurship and new initiatives leading to new medicines that save and transform patients’ lives.

Chiome Bioscience Inc. designs, develops, and sells monoclonal antibody products for medicine, diagnosis, testing, and life sciences. Chiome Bioscience is a clinical stage biotechnology company. Chiome's focus is on discovery and development of antibody-based therapeutics.

CytomX Therapeutics, Inc. is committed to changing the treatment of cancer with our novel Probody® therapeutic platform. We have a broad pipeline comprised of five clinical-stage programs, with even more in development. Our commitment to transforming lives with safer, more effective therapies is driven by our curiosity and passion for innovation, and our belief that by acting with integrity in an honest, respectful, ethical manner, we have the power to change lives. Our workplace embodies collaboration, open communication, celebrating our successes and holding each other to the highest possible standards. CytomX embraces diversity and seeks to enhance and maintain our culture of equity and inclusion which encourages individuals to be themselves, feel involved, respected and connected. We at CytomX believe that we benefit from each other’s ideas and experiences. We accept our differences and learn from one another, improve together, and embrace change to achieve our corporate and individual objectives. This belief applies to how we work together at CytomX, how we work with others outside CytomX, how we represent CytomX in our communities, and how we endeavor to bring our scientific innovations to a diverse patient population. CytomX acknowledges the importance of diversity, equity and inclusion initiatives and that they require an evolving and ongoing commitment. CytomX is an equal opportunity employer and does not discriminate against any individual or potential candidate because of race, color, religion, sex, national origin, sexual preference or any other legally protected category. CytomX is located in South San Francisco, California, the birthplace of biotechnology. Learn more about us and how we are advancing science to treat cancer differently at www.cytomX.com.

Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on oncology and immunology. The Company is building its robust portfolio and differentiated pipeline through internal R&D capability, collaborations with co-discovery and co-development partners and select acquisitions. The Company’s proprietary antibody technology platforms Harbour Mice® generate fully human monoclonal antibodies in two heavy and two light chain (H2L2) format, as well as heavy chain only (HCAb) format. Building upon the HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) are capable of delivering tumor killing effects unachievable by traditional combination therapies. Integrating Harbour Mice® with single B cell cloning platform, our antibody discovery engine is highly unique and efficient for development of next generation therapeutic antibodies.

Iksuda Therapeutics is a biotechnology company focussed on the development of a new generation of antibody drug conjugates (ADCs) targeting difficult-to-treat haematological and solid tumours. Iksuda’s pipeline of ADCs is centred on a portfolio of non-prodrug/prodrug DNA and protein alkylating payloads in combination with stable conjugation chemistries including its proprietary PermaLink® platform.

Mythic Therapeutics is a product-platform company that is pioneering a powerful new approach to improving the effectiveness of antibody-drug conjugates (ADCs) and other antibody-based therapeutics. Our technology dramatically increases therapeutic potency without compromising safety, thereby unlocking the full potential of targeted therapies against a broad array of tumor targets. At Mythic, we focus on patient-centered science and are driven to leave a lasting impact on cancer care.

Nectin Therapeutics is a biotech company focused on unlocking the power of the immune system. We are developing a collection of next-generation immunotherapy agents. Despite the unprecedented efficacy of existing immunotherapy agents, many patients either fail to respond, or following encouraging initial response, develop resistance over time. At Nectin, we have discovered novel resistance mechanisms and developed novel agents targeting these mechanisms for improved therapy. At Nectin, we are dedicated to the development of novel therapeutic options for cancer patients. We are developing a diverse pipeline of targeted antibodies based on the nectin pathways. These antibodies overcome inhibitory pathways deployed by the tumors and allow immune cells to effectively destroy cancer cells. Additionally, based on the unique expression patterns of several nectin proteins, we develop CAR-T and -NK drivers that directly target tumor cells in various indications, including hard-to-treat cancers.

Novelty Nobility Inc. is a private clinical stage biotech company located in Pangyo, South Korea, and Boston, Massachusetts. We are currently focused on the research of novel angiogenesis targets and develop antibody-based therapeutics in ophthalmology and oncology, where angiogenesis plays a key pathogenic role. Novelty Nobility, a unique name for a biotech company, stands for what we pursue – Novel Science, Noble Management. The emblem in the middle of our logo, which shapes a drug, symbolizes our belief that a new drug is born when novel science meets noble management.

Oncomatryx is a biopharmaceutical company focused on the tumor microenvironment. Oncomatryx has developed precision drugs and diagnostic devices that target the tumor stroma. Oncomatryx Antibody-Drug Conjugates (ADCs) and human-derived proteins target peritumoral fibroblasts, endothelial cells and extracellular matrix that promote tumor invasiveness, drug resistance and immunosuppression. Oncomatryx ADCs bear novel proprietary payloads and linker derivatives that render an optimal therapeutic index against pancreatic cancer in vivo. Oncomatryx OMTX705, an ADC which targets cancer-associated fibroblasts (CAFs), inhibits pancreatic tumor growth in patient-derived xenograft mice, both as single agent and in combination with chemotherapy.

OnCusp Therapeutics is transforming a growing portfolio of cutting-edge molecules into innovative treatments that deliver help and hope to cancer patients worldwide. The company is led by a founding team that has deep experience in business development, clinical development and building start-up biopharmaceutical company. OnCusp continually strives to optimize the largest value inflection point in the drug development value chain and believes that accelerating oncology drug innovation is the best way to deliver help and hope to cancer patients worldwide. OnCusp completed a $25m seed round from investors including Sequoia Capital China, Biotrack Capital, Oriza Seed Fund, and AIHC Capital. OnCusp has offices in New York and Shanghai.

Oxford BioTherapeutics (OBT) is a clinical stage oncology company based in Oxford, UK; San Jose, CA and Morristown, NJ, USA, with a pipeline of first-in-class immuno-oncology (IO) and antibody-drug conjugate (ADC) based therapies designed to fulfil major unmet patient needs in cancer therapeutics. Our lead asset, OBT076, is an Antibody Drug Conjugate (ADC) in Phase 1b clinical development. OBT076's dual mechanism of action allows it to act as a 'primer' to re-engage the patient's immune system while at the same time targeting cancer cells directly. OBT’s proprietary OGAP® target discovery platform is based on one of the world’s largest proprietary cancer membrane proteomic databases, with data on over 5,000 cancer cell proteins providing unique, highly qualified oncology targets, of which three programs are in clinical development in the USA and Europe. The company’s pipeline and development capabilities have been validated through multiple strategic partnerships, including with Boehringer Ingelheim, ImmunoGen and Kite Pharma as well as other world leaders in antibody development (such as Amgen, WuXi, Medarex (BMS), Alere (Abbott)).

Pacylex Pharmaceuticals is a clinical stage company developing a first-in-class, daily, oral cancer therapy with a novel, broad, mechanism of action, as a refractory cancer monotherapy and potential future combination therapy. PCLX-001 is a small molecule, N-myristoylation inhibitor that selectively kills cultured human leukemia and lymphoma cells ex-vivo, completely shrinks leukemia and lymphoma tumors in mice including tumors from drug resistant patients, and strongly inhibits growth of solid tumors in mice including breast and certain lung cancers. In an ongoing Phase 1 clinical trial, PCLX-001 has excellent bioavailability, half-life, and drug exposure with an acceptable safety profile to date when administered orally once daily to patients with relapsed advanced solid tumors or refractory B-cell lymphomas. Since this Phase 1 dose escalation clinical study is nearing the target recommended Phase 2 dose (RP2D), Pacylex is planning to expand the clinical program to AML at MD Anderson this fall in a DoD-supported Phase 2 study, as well as start two Phase 2 studies in DLBCL and solid tumor patients.

Pheon Therapeutics is leveraging two decades of ADC experience to build a novel pipeline of next generation ADCs which offer the potential to treat solid tumors and liquid cancers that do not respond to other treatments. Understanding there is no “one size fits all” in engineering ADCs, Pheon takes a methodical approach to ADC development. Using both novel and clinically validated monoclonal antibodies (mAbs) and arming them either with warheads from their proprietary payload platform which boasts a novel mechanism of action or with off-the-shelf linker payload combinations, Pheon is finely attuned to balancing safety and efficacy for each target. Pheon’s lead program exploits a novel target that is highly expressed in a broad range of solid tumors. The lead agent is expected to reach IND within the next 18 months. Backed by expert, specialist healthcare investors Atlas Venture, Brandon Capital, Forbion and Research Corporation Technologies, Pheon Therapeutics has a world class, proven leadership team that brings together the best of ADC engineering, clinical strategy and business expertise. The company has state-of-the-art medicinal chemistry laboratories in London (United Kingdom), and a commercial office in Boston (United States).

Junshi BioPharma is an innovation-driven biopharmaceutical company which is dedicated to the discovery and development of innovative drugs and their clinical research and commercialization on a global scale. Our mission is to provide patients with treatment options that work better and cost less. Based on the core platform technology of protein engineering, Junshi stands at the frontier of R&D of macromolecular drugs. With distinguished capability of innovative drug discovery, advanced biotechnological R&D, large-scale production capacity on the full industry chain and rapidly expanding drug candidate portfolio of tremendous market potential, Junshi has a leading edge in the PRC in the emerging field of immuno-oncology and for the treatment of autoimmune and metabolic diseases. Junshi is the first PRC company filing IND application and NDA application to the NMPA for anti-PD-1 monoclonal antibody, and also the first PRC company to receive IND approvals from the NMPA for anti-PCSK9 monoclonal antibody and anti-BLyS monoclonal antibody. Our vision is to become a pioneer in the area of translational medicine by developing first-in-class and best-in-class drugs through original innovation. With enrichment of our product pipelines and exploration of drug combination therapies, Junshi expanded its innovation to the R&D of more types of drugs, including small molecule drugs and antibody drug conjugates (or ADCs), as well as to the exploration of the next-generation innovative therapies for cancer and autoimmune diseases.

Tagworks Pharmaceuticals is a precision oncology company using our proprietary Click-to-Release treatment platform to develop a new standard of care for patients suffering from solid tumors by targeting clinically validated tumor markers that so far have remained out of reach of current therapies. Our lead program, TGW101, is an antibody-drug conjugate (ADC) targeting TAG72, a non-internalizing protein found on the surface of many solid tumor cells. We are developing a pipeline of novel cancer treatments leveraging our Click-to-Release technology in a range of therapeutic modalities, including ADCs and targeted radionuclide therapies. We are headquartered in the Netherlands with operations in the U.S. For more information, visit us at www.tagworkspharma.com.

VAR2 Pharmaceuticals is a privately held biotechnology company engaged in the design and development of proprietary therapeutic proteins targeting cancer-specific carbohydrate structures for multiple cancer indications. We have a portfolio of proteins with unique affinity and specificity for these cancer-associated carbohydrates for the development of treatments for cancers where there is no effective therapy, such as sarcoma, triple negative breast cancers and prostate cancer. The technology is based on groundbreaking discoveries made by Ali Salanti and his group, at University of Copenhagen, in collaboration with Mads Daugaard at University of British Columbia. The board and management team have a proven track record of building successful biotechnology companies, and the Scientific Advisory Board is comprised of leaders who have a long track record of developing cancer drugs and early stage biotech companies.

Vincerx Pharma Inc. is focused to address the unmet medical needs of our patients with paradigm-shifting therapeutics.

At Zumutor, we are on a mission to develop novel novel immuno onco-therapeutics that drive transformational improvements in cancer treatment through NK cell engagement. We leverage our proven proprietary antibody discovery- INABLR™ for fast track Antibody discovery and development. Our team works in collaboration with a world class Scientific Advisory Board with expertise in immuno-oncology and clinical development. Our lead asset (ZM008) is a first-in-class antibody that targets certain receptors that blocks NK cell inhibitory signal and enables NK cell activation to generate a potent immune response. Development is on track for an IND filing by Q2 2022 and Phase 1 clinical trial thereafter. We are headquartered in CIC Cambridge Campus, MA and R&D is carried out at ISO certified lab in Bangalore, India